The word peptide covers a wide range of molecules, and their legal standing varies just as widely. Some are FDA-approved drugs sold under brand names. Others are investigational, studied in trials but not approved for general use. A few circulate mostly through channels that a licensed pharmacy will not touch. If you are comparing providers, sorting a peptide into the right category is the first useful step.
This piece does not evaluate whether any peptide does what people hope it does. It is about status and access: what is legally available through a prescription, what drives the price, and how to tell a legitimate operation from a sloppy one.
Approved, investigational, or neither
Two of the compounds in this conversation are approved drugs with clear regulatory footing. Semaglutide and tirzepatide are FDA-approved GLP-1 medications sold under brand names by their manufacturers. That approval means a defined label, a known supply chain, and pharmacies that can dispense the branded product against a valid prescription.
Tesamorelin is also an approved product with a specific indication, which places it in the prescription world rather than the gray market. Its availability is narrower than the GLP-1 drugs, but it is a real, regulated medicine.
Semax sits in a different place. It is not FDA approved. It is investigational in the United States, and much of its clinical history is tied to research and use abroad. That distinction matters because an approval in one country is not an approval here.
Thymosin-alpha-1 is another example of a peptide with an international regulatory history that does not translate into US approval. Readers sometimes assume that a peptide sold overseas is therefore available through an American pharmacy the same way. It is not that simple.
How legitimate access actually works
The only channel worth considering is a licensed pharmacy filling a valid prescription written by a clinician who has evaluated you. For approved drugs, that can mean the branded product. For some peptides, it can mean a compounded preparation made by a 503A pharmacy or a 503B outsourcing facility, when a compounded version is legally permissible.
Compounding is not a loophole that makes any molecule available. Whether a given peptide can be compounded depends on its regulatory status and current FDA guidance, and that landscape shifts. A responsible provider works within those limits and can explain where a specific compound stands.
What drives cost
Price differences usually come from a few concrete factors. Branded approved drugs carry manufacturer pricing and, in some cases, insurance coverage. Compounded preparations are priced by the pharmacy and vary with sourcing and formulation. Telehealth platforms fold in the cost of the consultation and ongoing clinical contact. When one provider is far cheaper than the rest, ask what is different about the product and the oversight, not just the sticker.
Vetting a provider
A trustworthy operation shares a few traits. It requires a real clinical evaluation before prescribing. It names the pharmacy that fills the order and can tell you whether that pharmacy is a 503A or 503B facility. It is straightforward about the regulatory status of what it is offering, including whether a peptide is approved or investigational. And it connects you with a licensed clinician you can reach with questions.
Be cautious with any provider that skips the evaluation, promises outcomes, or blurs the line between an approved drug and something sold for research. Vague sourcing is a warning sign on its own.
The bottom line
A mixed evidence picture is also a mixed legal picture. Some of these peptides are approved medicines you can obtain through ordinary prescription channels. Others are investigational and are not, and no amount of marketing changes that. Use a licensed clinician to decide what, if anything, is appropriate for you, and treat this as general information rather than medical advice.